{"schema_version":"1","generated_at":"2026-10-28T06:52:16.396Z","data_as_of":null,"url":"https://www.findmykol.com/kol/eyal-attar","json_url":"https://www.findmykol.com/kol/eyal-attar/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"eyal-attar","name":"Eyal Attar","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Aprea Therapeutics","institution_url":"https://www.findmykol.com/institution/aprea-therapeutics","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1407847965","orcid":"0000-0002-1959-8079","openalex":"A5089274301"},"summary":"Eyal Attar is an Oncology physician affiliated with Aprea Therapeutics. OpenAlex indexes 215 publications with 11,345 citations (h-index 48); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":215,"cited_by_count":11345,"h_index":48,"latest_activity_year":2023,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00742625","title":"Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","phase":"PHASE1/PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT00742625","trial_url":"https://www.findmykol.com/trial/NCT00742625"}],"source":"trials"},"prescribing":{"data_year":2020,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":58.6,"classes_total":1,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":58.6,"drugs":[{"name":"Sprycel","share_pct":100}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":41.4,"classes_total":1,"classes":[{"class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":41.4,"drugs":[{"name":"Famciclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2019,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2007,"last":2011},"rows_total":5,"shown":3,"withheld":2,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"K23CA118419","title":"Defining clinical efficacy and markers predicting response to bortezomib in AML","fiscal_year":2011,"amount_usd":"143370","organization":"MASSACHUSETTS GENERAL HOSPITAL","source_url":"https://reporter.nih.gov/quickSearch/K23CA118419"},{"project":"K23CA118419","title":"Defining clinical efficacy and markers predicting response to bortezomib in AML","fiscal_year":2010,"amount_usd":"143370","organization":"MASSACHUSETTS GENERAL HOSPITAL","source_url":"https://reporter.nih.gov/quickSearch/K23CA118419"},{"project":"K23CA118419","title":"Defining clinical efficacy and markers predicting response to bortezomib in AML","fiscal_year":2009,"amount_usd":"142560","organization":"MASSACHUSETTS GENERAL HOSPITAL","source_url":"https://reporter.nih.gov/quickSearch/K23CA118419"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","year":2023,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(22)00403-3","status":"verified"},{"title":"Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for <i>TP53</i>-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes","year":2022,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.22.00181","status":"verified"},{"title":"Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors","year":2022,"journal":"ESMO Open","source_url":"https://doi.org/10.1016/j.esmoop.2022.100573","status":"verified"},{"title":"Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes","year":2021,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.20.02341","status":"verified"},{"title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","year":2020,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2020001503","status":"verified"}],"source":"works"},"contact":{"address_1":"55 FRUIT ST","address_2":"YAW 7B HEMATOLOGY ONCOLOGY","city":"Boston","state":"MA","zip":"021142621","phone":"617-726-8731","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1407847965","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"funding":2,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2012-10-23","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2020},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}